Persistent Asset Partners’s AN2 Therapeutics ANTX Stock Holding History

Persistent Asset Partners’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-38,155	Closed	-$130K	–	813
2026 Q1	$130K	Buy	+38,155	New	+$78.7K	0.05%	227

Other funds holding ANTX

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Persistent Asset Partners's ANTX Position: Q2 2026 in Review

Persistent Asset Partners sold out of AN2 Therapeutics (ANTX) in Q2 2026, closing a stake of 38,155 shares — an estimated $130K sold.

Persistent Asset Partners first reported a position in ANTX in Q1 2026 and held it in 1 quarter. The position peaked at $130K in Q1 2026. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

Persistent Asset Partners reported no remaining AN2 Therapeutics position as of Q2 2026 after selling out during the quarter.
Persistent Asset Partners sold 38,155 AN2 Therapeutics shares in Q2 2026, an estimated $130K.
Persistent Asset Partners first reported a position in AN2 Therapeutics in Q1 2026 and held it in 1 quarter.
Persistent Asset Partners's AN2 Therapeutics position peaked at $130K in Q1 2026.
66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.